CSS
MDGL icon

Cubist Systematic Strategies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cubist Systematic Strategies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-800
Closed -$265K – 3316
2025
Q1 		$265K Buy
+800
New +$263K ﹤0.01% 2427

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cubist Systematic Strategies's MDGL Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2025: 17,889 shares worth $8.2M. The stake represents 0.04% of the portfolio and ranks #667 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in MDGL as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in MDGL in Q3 2014 and has held it in 25 quarters since. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Cubist Systematic Strategies held 17,889 shares of Madrigal Pharmaceuticals worth $8.2M as of Q3 2025.
  • Madrigal Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Madrigal Pharmaceuticals made up 0.04% of Cubist Systematic Strategies's portfolio in Q3 2025, its #667 holding.
  • Cubist Systematic Strategies first reported a position in Madrigal Pharmaceuticals in Q3 2014 and has held it in 25 quarters since.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.